Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

CORRECTION: Fortress Biotech's Cyprium Therapeutics Announces FDA Extended NDA Target Date For CUTX-101 To September 30, 2025; Sentynl Responsible For Development And Commercialization; Cyprium Retains Priority Review Voucher Rights, Eligible For Up To $129M Royalties And Milestones

Author: Benzinga Newsdesk | January 16, 2025 04:25pm

r

Posted In: FBIO